FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897665263> ?p ?o ?g. }

• W2897665263 endingPage "184" @default.
• W2897665263 startingPage "178" @default.
• W2897665263 abstract "Abstract Background Zoledronic acid (ZA), a potent bisphosphonate used for treatment of bone metastasis, has high bone affinity. This post hoc analysis evaluated the effects of long-term treatment and reduction in dosing frequency of ZA on bone saturation. Materials and Methods Pharmacokinetic data from three independent studies, OPTIMIZE-2 (patients receiving ≥9 doses of bisphosphonates) and two phase I studies, CZOL4460503 and CZOL4460506 (patients who were bisphosphonate naïve/bisphosphonate free for ≥1 year after previous dosing), were pooled. Serial urine and plasma samples were used as surrogate markers to determine ZA plasma area under the curve (AUC) over 6 hours (AUC0–6h) and dose excreted in urine over 6 hours (urine0–6h). Potential relationships between the number of years for which patients had been treated previously at time of study entry and AUC0–6h or urine0–6h were analyzed graphically. Results Creatinine clearances for patients were similar across the three studies and at all time points analyzed. The levels of AUC0–6h ZA in plasma at week 0 in every (q) 4 and q12 weekly arms of OPTIMIZE-2 were 0.366 h × mg/L and 0.397 h × mg/L compared with 0.345 h × mg/L and 0.356 h × mg/L in CZOL4460503 and CZOL4460506, respectively. In OPTIMIZE-2, the AUC0–6h ZA plasma levels were the same (0.428 h × mg/L) at week 36 in both q4 and q12 arms. The levels of ZA urine0–6h at week 36 in OPTIMIZE-2 (q4 and q12 week arms), CZOL4460503, and CZOL4460506 were 36.6%, 30.8%, 26.5%, and 27.3%, respectively. Conclusion Long-term ZA treatment may not impact bone saturation, and ZA dosing frequency does not seem to influence drug retention rates. Implications for Practice Zoledronic acid (ZA), used along with standard antineoplastic therapy to treat bone metastases associated with solid tumors and multiple myeloma, requires frequent (every 3–4 or every 12 weeks) long-term administration. This may result in bone saturation and subsequently lead to a higher risk of adverse events such as osteonecrosis of the jaw and atypical fractures. This post hoc analysis used surrogate markers to demonstrate that prolonged ZA administration does not cause bone saturation. Furthermore, reduction in ZA dosing frequency does not affect its retention level in bones over time. These findings will help in addressing clinicians' concerns regarding prolonged ZA administration." @default.
• W2897665263 created "2018-10-26" @default.
• W2897665263 creator A5015687794 @default.
• W2897665263 creator A5018617106 @default.
• W2897665263 creator A5089417324 @default.
• W2897665263 date "2018-10-08" @default.
• W2897665263 modified "2023-10-14" @default.
• W2897665263 title "Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long‐Term Dosing" @default.
• W2897665263 cites W1889985059 @default.
• W2897665263 cites W1966578684 @default.
• W2897665263 cites W1975805439 @default.
• W2897665263 cites W1993952498 @default.
• W2897665263 cites W2025672294 @default.
• W2897665263 cites W2033254267 @default.
• W2897665263 cites W2035230005 @default.
• W2897665263 cites W2041868422 @default.
• W2897665263 cites W2045369683 @default.
• W2897665263 cites W2050358330 @default.
• W2897665263 cites W2061202924 @default.
• W2897665263 cites W2061896598 @default.
• W2897665263 cites W2068522538 @default.
• W2897665263 cites W2076769374 @default.
• W2897665263 cites W2077217176 @default.
• W2897665263 cites W2099178340 @default.
• W2897665263 cites W2113701976 @default.
• W2897665263 cites W2119505268 @default.
• W2897665263 cites W2121283077 @default.
• W2897665263 cites W2123367264 @default.
• W2897665263 cites W2141911566 @default.
• W2897665263 cites W2142670098 @default.
• W2897665263 cites W2151409604 @default.
• W2897665263 cites W2158771095 @default.
• W2897665263 cites W2274443098 @default.
• W2897665263 cites W2581286732 @default.
• W2897665263 cites W2612478849 @default.
• W2897665263 cites W2765774285 @default.
• W2897665263 cites W3205206586 @default.
• W2897665263 doi "https://doi.org/10.1634/theoncologist.2018-0218" @default.
• W2897665263 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6369945" @default.
• W2897665263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30297386" @default.
• W2897665263 hasPublicationYear "2018" @default.
• W2897665263 type Work @default.
• W2897665263 sameAs 2897665263 @default.
• W2897665263 citedByCount "4" @default.
• W2897665263 countsByYear W28976652632019 @default.
• W2897665263 countsByYear W28976652632020 @default.
• W2897665263 countsByYear W28976652632021 @default.
• W2897665263 countsByYear W28976652632023 @default.
• W2897665263 crossrefType "journal-article" @default.
• W2897665263 hasAuthorship W2897665263A5015687794 @default.
• W2897665263 hasAuthorship W2897665263A5018617106 @default.
• W2897665263 hasAuthorship W2897665263A5089417324 @default.
• W2897665263 hasBestOaLocation W28976652631 @default.
• W2897665263 hasConcept C112705442 @default.
• W2897665263 hasConcept C121608353 @default.
• W2897665263 hasConcept C126322002 @default.
• W2897665263 hasConcept C126894567 @default.
• W2897665263 hasConcept C2776326535 @default.
• W2897665263 hasConcept C2776541429 @default.
• W2897665263 hasConcept C2777251235 @default.
• W2897665263 hasConcept C2777288759 @default.
• W2897665263 hasConcept C2777783956 @default.
• W2897665263 hasConcept C2779013556 @default.
• W2897665263 hasConcept C2780026642 @default.
• W2897665263 hasConcept C2780306776 @default.
• W2897665263 hasConcept C67761136 @default.
• W2897665263 hasConcept C71924100 @default.
• W2897665263 hasConcept C76318530 @default.
• W2897665263 hasConcept C98274493 @default.
• W2897665263 hasConceptScore W2897665263C112705442 @default.
• W2897665263 hasConceptScore W2897665263C121608353 @default.
• W2897665263 hasConceptScore W2897665263C126322002 @default.
• W2897665263 hasConceptScore W2897665263C126894567 @default.
• W2897665263 hasConceptScore W2897665263C2776326535 @default.
• W2897665263 hasConceptScore W2897665263C2776541429 @default.
• W2897665263 hasConceptScore W2897665263C2777251235 @default.
• W2897665263 hasConceptScore W2897665263C2777288759 @default.
• W2897665263 hasConceptScore W2897665263C2777783956 @default.
• W2897665263 hasConceptScore W2897665263C2779013556 @default.
• W2897665263 hasConceptScore W2897665263C2780026642 @default.
• W2897665263 hasConceptScore W2897665263C2780306776 @default.
• W2897665263 hasConceptScore W2897665263C67761136 @default.
• W2897665263 hasConceptScore W2897665263C71924100 @default.
• W2897665263 hasConceptScore W2897665263C76318530 @default.
• W2897665263 hasConceptScore W2897665263C98274493 @default.
• W2897665263 hasFunder F4320310388 @default.
• W2897665263 hasIssue "2" @default.
• W2897665263 hasLocation W28976652631 @default.
• W2897665263 hasLocation W28976652632 @default.
• W2897665263 hasLocation W28976652633 @default.
• W2897665263 hasLocation W28976652634 @default.
• W2897665263 hasOpenAccess W2897665263 @default.
• W2897665263 hasPrimaryLocation W28976652631 @default.
• W2897665263 hasRelatedWork W2004325424 @default.
• W2897665263 hasRelatedWork W2028965714 @default.
• W2897665263 hasRelatedWork W2080937445 @default.
• W2897665263 hasRelatedWork W2080969318 @default.
• W2897665263 hasRelatedWork W2090418955 @default.

• next